Nasal spray for allergies to launch next month

Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.

With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.

Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.

This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.

The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.

Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.

Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.

To guide public health and vaccination strategies, researchers assessed a variety of factors regarding community-acquired pneumonia and its causes.